Clicky

Zynerba Pharmaceuticals, Inc.(ZYNE)

Description: Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates, including ZYN002 and ZYN001, which represent cannabinoid therapeutics for several indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In preclinical animal studies, ZYN002's permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. ZYN001 is a pro-drug of delta-9-tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. In preclinical animal studies, ZYN001 demonstrated effective skin permeation with sustained delivery and rapid conversion of ZYN001 to THC.


Keywords: Pharmaceutical Drugs Pain Entheogens Psychoactive Drugs Chemical Compounds Cannabidiol Osteoarthritis Epilepsy Resorcinols CBD Circulatory System Neuropathic Pain Tetrahydrocannabinol Cannabinoid Fibromyalgia Transdermal Cannabinol Fragile X Syndrome Natural Phenols Synthetic Cannabinoids Refractory Epilepsy

Home Page: www.zynerba.com

ZYNE Technical Analysis

80 West Lancaster Avenue
Devon, PA 19333
United States
Phone: 484 581 7505


Officers

Name Title
Mr. Armando Anido MBA Chairman & CEO
Ms. Terri B. Sebree Pres
Mr. James E. Fickenscher CFO & VP of Corp. Devel.
Mr. Albert P. Parker II Chief Legal Officer & Corp. Sec.
Mr. Joseph Apostolico VP of HR

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.5356
Price-to-Sales TTM: 1152.6944
IPO Date: 2015-08-05
Fiscal Year End: December
Full Time Employees: 28
Back to stocks